Results 261 to 270 of about 173,203 (312)

GLP‐1RA and Liver Fibrosis Progression in MASLD and Type 2 Diabetes: Target Trial Emulation Using Propensity Score Matching

Liver International, Volume 45, Issue 12, December 2025.
ABSTRACT Background and Aims GLP‐1 receptor agonists (GLP‐1RA) are widely used in type 2 diabetes mellitus (T2DM) and may confer hepatoprotective effects in metabolic dysfunction‐associated steatotic liver disease (MASLD). Their impact on liver fibrosis progression in real‐world clinical settings remains unclear.
Jonggi Choi, Tushar Kamath, Vy H. Nguyen, Eric Przybyszewski, Jiunn Song, Allison Carroll, Megan Michta, Erik Almazan, Tracey G. Simon, Raymond T. Chung   +9 more
wiley   +1 more source

Concurrent nonalcoholic fatty liver disease may decrease liver fibrosis severity in patients with primary biliary cholangitis. [PDF]

BMC Gastroenterol
Ren W, Wang Z, Liu X, Liu X, Ma D, Jin Q, Wang J, Feng J, Rao H, Wang X, Huang R.   +10 more
europepmc   +1 more source

Efficacy of traditional Chinese medicine combined with Silibinin on nonalcoholic fatty liver disease: A meta-analysis and systematic review

Xiang Zhang, Zhenghao Jiang, Xiaoliang Jin, Qiujun Zhou   +3 more
openalex   +1 more source

Oxidative stress and depletion of hepatic long-chain polyunsaturated fatty acids may contribute to nonalcoholic fatty liver disease

, 2004
Luis A. Videla, Ramón Rodrigo, Julia Araya, Jaime Poníachik   +3 more
openalex   +2 more sources

The Genetic Blueprint of Obesity: From Pathogenesis to Novel Therapies

Obesity Reviews, Volume 26, Issue 12, December 2025.
ABSTRACT Obesity is a chronic metabolic disease characterized by disturbances in energy homeostasis, leading to excessive fat accumulation. The pathogenesis of the disease is shaped by a complex interplay of genetic, epigenetic, biological, psychological, and environmental factors.
Gašper Tonin, Stjepan Eržen, Zala Mlinarič, Dubravka Jurišić Eržen, Simon Horvat, Tanja Kunej, Jasna Klen   +6 more
wiley   +1 more source

Association of Components of Metabolic Syndrome and the Progression of Nonalcoholic Fatty Liver Disease. [PDF]

Am J Gastroenterol
Le P, Tatar M, Rothberg MB, Wilson LA, Allende D, Diehl AM, Loomba R, Chalasani N, Neuschwander-Tetri BA, Kowdley K, Sanyal AJ, Tonascia J, Dasarathy S, NASH Clinical Research Network (CRN).   +13 more
europepmc   +1 more source

GLM7 – A Novel Composite Glycolipid Index Derived from Routine Health Indicators for Enhanced Diagnosis and Prediction of Multimorbidity

Advanced Science, Volume 12, Issue 42, November 13, 2025.
This study leverages NHANES data to analyze 49 routine indicators, identifying the top 10 diagnostic markers for five major diseases and introducing GLM7, a novel indicator. Restricted cubic spline analyses, forest plot evaluations, and XGBoost modeling demonstrate conventional indicators' efficacy and GLM7's value for disease diagnosis/prediction ...
Zhihua Wang, Shuo Chen, Xiaojun Feng, Xi Chen, Paul C Evans, Hans Strijdom, Yu Ding, Jianping Weng, Suowen Xu   +8 more
wiley   +1 more source

Causal association between macrophage migration inhibitory factor and nonalcoholic fatty liver disease: A two-sample Mendelian randomization study. [PDF]

Medicine (Baltimore)
Yu F, Fang Y, Fang P, Chen D.
europepmc   +1 more source

Relationship between obesity, metabolic syndrome, and nonalcoholic fatty liver disease in the elderly agricultural and fishing population of Taiwan

, 2014
Shen HC, Zhao ZH, Hu YC, Chen YF, Tung TH   +4 more
openalex   +1 more source

Low muscle quality index is associated with increased risk of advanced fibrosis in adult patients with nonalcoholic fatty liver disease: NHANES 2011–2014

Xinxing Tantai, Qiuju Ran, Wen Zhang, Shuyue Tuo, Na Liu, Shejiao Dai, Jinhai Wang, Chenyang Qiao   +7 more
openalex   +1 more source